Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1969 1
1975 1
1983 1
1991 1
1993 1
1994 3
1995 2
1996 1
1997 2
1998 1
2000 1
2001 1
2003 1
2004 3
2005 2
2006 2
2008 2
2009 2
2010 1
2013 1
2014 1
2017 2
2018 1
2019 5
2020 5
2021 7
2022 4
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

49 results

Results by year

Filters applied: . Clear all
Page 1
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.
Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, Gelber RD, de Azambuja E, Fielding A, Balmaña J, Domchek SM, Gelmon KA, Hollingsworth SJ, Korde LA, Linderholm B, Bandos H, Senkus E, Suga JM, Shao Z, Pippas AW, Nowecki Z, Huzarski T, Ganz PA, Lucas PC, Baker N, Loibl S, McConnell R, Piccart M, Schmutzler R, Steger GG, Costantino JP, Arahmani A, Wolmark N, McFadden E, Karantza V, Lakhani SR, Yothers G, Campbell C, Geyer CE Jr; OlympiA Clinical Trial Steering Committee and Investigators. Tutt ANJ, et al. N Engl J Med. 2021 Jun 24;384(25):2394-2405. doi: 10.1056/NEJMoa2105215. Epub 2021 Jun 3. N Engl J Med. 2021. PMID: 34081848 Free PMC article. Clinical Trial.
Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer.
Partridge AH, Niman SM, Ruggeri M, Peccatori FA, Azim HA Jr, Colleoni M, Saura C, Shimizu C, Sætersdal AB, Kroep JR, Mailliez A, Warner E, Borges VF, Amant F, Gombos A, Kataoka A, Rousset-Jablonski C, Borstnar S, Takei J, Lee JE, Walshe JM, Ruíz-Borrego M, Moore HCF, Saunders C, Bjelic-Radisic V, Susnjar S, Cardoso F, Smith KL, Ferreiro T, Ribi K, Ruddy K, Kammler R, El-Abed S, Viale G, Piccart M, Korde LA, Goldhirsch A, Gelber RD, Pagani O; International Breast Cancer Study Group; POSITIVE Trial Collaborators. Partridge AH, et al. N Engl J Med. 2023 May 4;388(18):1645-1656. doi: 10.1056/NEJMoa2212856. N Engl J Med. 2023. PMID: 37133584 Free PMC article. Clinical Trial.
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.
von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, Suter T, Arahmani A, Rouchet N, Clark E, Knott A, Lang I, Levy C, Yardley DA, Bines J, Gelber RD, Piccart M, Baselga J; APHINITY Steering Committee and Investigators. von Minckwitz G, et al. N Engl J Med. 2017 Jul 13;377(2):122-131. doi: 10.1056/NEJMoa1703643. Epub 2017 Jun 5. N Engl J Med. 2017. PMID: 28581356 Free PMC article. Clinical Trial.
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.
Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, Diaz R, Alings M, Lonn EM, Anand SS, Widimsky P, Hori M, Avezum A, Piegas LS, Branch KRH, Probstfield J, Bhatt DL, Zhu J, Liang Y, Maggioni AP, Lopez-Jaramillo P, O'Donnell M, Kakkar AK, Fox KAA, Parkhomenko AN, Ertl G, Störk S, Keltai M, Ryden L, Pogosova N, Dans AL, Lanas F, Commerford PJ, Torp-Pedersen C, Guzik TJ, Verhamme PB, Vinereanu D, Kim JH, Tonkin AM, Lewis BS, Felix C, Yusoff K, Steg PG, Metsarinne KP, Cook Bruns N, Misselwitz F, Chen E, Leong D, Yusuf S; COMPASS Investigators. Eikelboom JW, et al. N Engl J Med. 2017 Oct 5;377(14):1319-1330. doi: 10.1056/NEJMoa1709118. Epub 2017 Aug 27. N Engl J Med. 2017. PMID: 28844192 Free article. Clinical Trial.
Expression of the transcription factor c-Ets1 correlates with the occurrence of invasive processes during normal and pathological development.
Vandenbunder B, Queva C, Desbiens X, Wernert N, Stehelin D. Vandenbunder B, et al. Invasion Metastasis. 1994-1995;14(1-6):198-209. Invasion Metastasis. 1994. PMID: 7657513 Review.
The protein encoded by the c-ets1 proto-oncogene is a member of a new family of transcription factors. Cellular regulatory sequences responsive to the c-Ets1 proteins include a urokinase-type plasminogen activator (uPA) gene enhancer, the stromelysin 1 and the colla …
The protein encoded by the c-ets1 proto-oncogene is a member of a new family of transcription factors. Cellular regulatory sequences …
Molecular based equation of state for shocked liquid nitromethane.
Desbiens N, Bourasseau E, Maillet JB, Soulard L. Desbiens N, et al. J Hazard Mater. 2009 Jul 30;166(2-3):1120-6. doi: 10.1016/j.jhazmat.2008.12.083. Epub 2008 Dec 25. J Hazard Mater. 2009. PMID: 19217711
Unlike previous major works, this equation of state is not based on extended integration schemes [P.C. Lysne, D.R. Hardesty, Fundamental equation of state of liquid nitromethane to 100 kbar, J. ...Sim. 33 (2007) 1061; A. Hervouet, N. Desbiens, E. Bourasseau, J.-B. M …
Unlike previous major works, this equation of state is not based on extended integration schemes [P.C. Lysne, D.R. Hardesty, Fundamen …
c-Myc potentiates the mitochondrial pathway of apoptosis by acting upstream of apoptosis signal-regulating kinase 1 (Ask1) in the p38 signalling cascade.
Desbiens KM, Deschesnes RG, Labrie MM, Desfossés Y, Lambert H, Landry J, Bellmann K. Desbiens KM, et al. Biochem J. 2003 Jun 1;372(Pt 2):631-41. doi: 10.1042/BJ20021565. Biochem J. 2003. PMID: 12646044 Free PMC article.
Cisplatin treatment of Rat1 cells with deregulated expression of c-Myc resulted in nuclear fragmentation that was accompanied in all cells by the activation of Bax and the translocation of cytochrome c from the mitochondria to the cytoplasm. ...Remarkably, overexpre …
Cisplatin treatment of Rat1 cells with deregulated expression of c-Myc resulted in nuclear fragmentation that was accompanied in all …
Distance to the pediatric oncology center does not affect survival in children with acute lymphoblastic leukemia: a report from CYP-C.
Lemieux-Sarrasin D, Pelland-Marcotte MC, Simonyan D, Martineau É, Desbiens B, Michon B. Lemieux-Sarrasin D, et al. Leuk Lymphoma. 2021 Apr;62(4):960-966. doi: 10.1080/10428194.2020.1849673. Epub 2020 Nov 24. Leuk Lymphoma. 2021. PMID: 33231123
We aimed to determine whether remoteness is associated with cancer outcomes in pediatric acute lymphoblastic leukemia (ALL). Canadian children with ALL entered in the CYP-C registry were included. The predictive impact of remoteness on overall survival (OS), relapse, and t …
We aimed to determine whether remoteness is associated with cancer outcomes in pediatric acute lymphoblastic leukemia (ALL). Canadian childr …
Does the transcription factor c-ets1 take part in the regulation of angiogenesis and tumor invasion?
Vandenbunder B, Wernert N, Queva C, Desbiens X, Stehelin D. Vandenbunder B, et al. Folia Biol (Praha). 1994;40(5):301-13. Folia Biol (Praha). 1994. PMID: 7534726 Review.
The c-ets1 proto-oncogene encodes a transcription factor that binds a GGAA/T purine rich core DNA sequence. During normal as well as pathological development, the expression of c-ets1 is associated with the occurrence of invasive processes, either in invading cells …
The c-ets1 proto-oncogene encodes a transcription factor that binds a GGAA/T purine rich core DNA sequence. During normal as well as …
49 results